Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stockholders of US pharmaceutical group Wyeth have voted against splitting the roles of chairman and CEO at its annual meeting.
Subscribe to our email newsletter
In addition, stockholders voted to defeat stockholder proposals regarding: disclosing the company’s animal welfare policy; preparing a report on limiting the supply of prescription drugs in Canada, and providing additional disclosure of political contributions.
Another stockholder proposal – to seek recoupment of incentive bonuses from Wyeth management when business performance targets were reasonably determined not to have been achieved – was passed.
Highlighting the company’s performance over the year, chairman and CEO Robert Essner said: “Our strong performance reflected the convergence of several factors, including solidifying our position as a leading biotech company and realizing the success of our primary care sales force model.”